1,210 research outputs found

    Applicability valuation for evaluation of surface deflection in automotive outer panels

    Get PDF
    Upon unloading in a forming process there is elastic recovery, which is the release of the elastic strains and the redistribution of the residual stresses through the thickness direction, thus producing surface deflection. It causes changes in shape and dimensions that can create major problem in the external appearance of outer panels. Thus surface deflection prediction is an important issue in sheet metal forming industry. Many factors could affect surface deflection in the process, such as material variations in mechanical properties, sheet thickness, tool geometry, processing parameters and lubricant condition. The shape and dimension problem in press forming is defined as a trouble mainly caused by the elastic recovery of materials during the forming. The use of high strength steel sheets in the manufacturing of automobile outer panels has increased in the automotive industry over the years because of its lightweight and fuel-efficient improvement. But one of the major concerns of stamping is surface deflection in the formed outer panels. Hence, to be cost effective, accurate prediction must be made of its formability. The automotive industry places rigi

    Mode of substrate binding and specificity for ketohexokinase across isozymes implies an induced-fit mechanism

    Get PDF
    Ketohexokinase (KHK), in an adenosine triphosphate (ATP) dependent reaction, catalyzes the first reaction in fructose metabolism, which converts the furanose form of D-fructose into fructose-1-phosphate. This enzyme has become a target for pharmacological development against fatty liver and metabolic syndrome. KHK exists in two isoforms, A and C, which differs by alternative splicing of exon 3 which encodes 45 out of 298 amino acids. Normally KHK exists as a homodimer and is comprised of an alpha/beta domain interlocking with a β-clasp domain. For KHK-C, there appear to be at least two conformations of the β-clasp domain. Previous work on KHK-A reveals it does not adopt the same conformations. A structure of the mouse KHK-A in its unliganded form is solved and shows that these two conformations also exist for KHK-A. Furthermore, this property is conserved across species. While crystals of human KHK-A in its unliganded form were grown, a structure was not achieved. However, unpublished structures of human KHK-A in its unliganded form also shows different conformations in β-clasp domain when in juxtaposition with the same enzyme complex with ligands. Defining the role of conformational changes in KHK-A is important, because this isozyme has been reported to have a role in cancer metastasis

    Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1

    Get PDF
    Cancer therapeutics: Extending a drug's reach A new drug that blocks heat shock proteins (HSPs), helper proteins that are co-opted by cancer cells to promote tumor growth, shows promise for cancer treatment. Several drugs have targeted HSPs, since cancer cells are known to hijack these helper proteins to shield themselves from destruction by the body. However, the drugs have had limited success. Hye-Kyung Park and Byoung Heon Kang at Ulsan National Institutes of Science and Technology in South Korea and coworkers noticed that the drugs were not absorbed into mitochondria, a key cellular compartment, and HSPs in this compartment were therefore not being blocked. They identified a new HSP inhibitor that can reach every cellular compartment and inhibit all HSPs. Testing in mice showed that this inhibitor effectively triggered death of tumor cells, and therefore shows promise for anti-cancer therapy. The Hsp90 family proteins Hsp90, Grp94, and TRAP1 are present in the cell cytoplasm, endoplasmic reticulum, and mitochondria, respectively; all play important roles in tumorigenesis by regulating protein homeostasis in response to stress. Thus, simultaneous inhibition of all Hsp90 paralogs is a reasonable strategy for cancer therapy. However, since the existing pan-Hsp90 inhibitor does not accumulate in mitochondria, the potential anticancer activity of pan-Hsp90 inhibition has not yet been fully examined in vivo. Analysis of The Cancer Genome Atlas database revealed that all Hsp90 paralogs were upregulated in prostate cancer. Inactivation of all Hsp90 paralogs induced mitochondrial dysfunction, increased cytosolic calcium, and activated calcineurin. Active calcineurin blocked prosurvival heat shock responses upon Hsp90 inhibition by preventing nuclear translocation of HSF1. The purine scaffold derivative DN401 inhibited all Hsp90 paralogs simultaneously and showed stronger anticancer activity than other Hsp90 inhibitors. Pan-Hsp90 inhibition increased cytotoxicity and suppressed mechanisms that protect cancer cells, suggesting that it is a feasible strategy for the development of potent anticancer drugs. The mitochondria-permeable drug DN401 is a newly identified in vivo pan-Hsp90 inhibitor with potent anticancer activity

    Multi-Rate VAE: Train Once, Get the Full Rate-Distortion Curve

    Full text link
    Variational autoencoders (VAEs) are powerful tools for learning latent representations of data used in a wide range of applications. In practice, VAEs usually require multiple training rounds to choose the amount of information the latent variable should retain. This trade-off between the reconstruction error (distortion) and the KL divergence (rate) is typically parameterized by a hyperparameter β\beta. In this paper, we introduce Multi-Rate VAE (MR-VAE), a computationally efficient framework for learning optimal parameters corresponding to various β\beta in a single training run. The key idea is to explicitly formulate a response function that maps β\beta to the optimal parameters using hypernetworks. MR-VAEs construct a compact response hypernetwork where the pre-activations are conditionally gated based on β\beta. We justify the proposed architecture by analyzing linear VAEs and showing that it can represent response functions exactly for linear VAEs. With the learned hypernetwork, MR-VAEs can construct the rate-distortion curve without additional training and can be deployed with significantly less hyperparameter tuning. Empirically, our approach is competitive and often exceeds the performance of multiple β\beta-VAEs training with minimal computation and memory overheads.Comment: 22 pages, 9 figure

    Numerical Analysis of IEEE 802.11 Broadcast Scheme in Multihop Wireless Ad Hoc Networks

    Full text link
    Abstract. In this paper, we study the performance of IEEE 802.11 broadcast scheme in multihop wireless networks using an analytical model. Previous works have evaluated the performance of IEEE 802.11 proto-col assuming unicast communication, but there has not been an analysis considering broadcast communication. Analyzing performance of broad-cast communication is important because multicast communication is gaining attention in wireless networks with numerous potential applica-tions. Broadcast in IEEE 802.11 does not use virtual carrier sensing and thus only relies on physical carrier sensing to reduce collision. For this study, we define a successful broadcast transmission to be the case when all of the sender’s neighbors receive the broadcast frame correctly, and calculate the achievable throughput.

    Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study

    Get PDF
    Introduction: Anti-cyclic citrullinated peptide autoantibodies (anti-CCP) are the most specific serologic marker for rheumatoid arthritis (RA). Genetic polymorphisms in a citrullinating (or deiminating) enzyme, peptidyl arginine deiminase type IV (PADI4) have been reproducibly associated with RA susceptibility in several populations. We investigated whether PADI4 polymorphisms contribute to anti-CCP-negative as well as -positive RA, whether they influence disease severity (erosive joint status), and whether they interact with two major risk factors for RA, Human Leukocyte Antigen-DRB1 (HLA-DRB1) shared epitope (SE) alleles and smoking, depending on anti-CCP and erosive joint status.Methods: All 2,317 unrelated Korean subjects including 1,313 patients with RA and 1,004 unaffected controls were genotyped for three nonsynonymous (padi4_89, padi4_90, and padi4_92) and one synonymous (padi4_104) singlenucleotide polymorphisms (SNPs) in PADI4 and for HLA-DRB1 by direct DNA sequence analysis. Odds ratios (OR) were calculated by multivariate logistic regression. Interaction was evaluated by attributable proportions (AP), with 95% confidence intervals (CI).Results: A functional haplotype of the three fully correlated nonsynonymous SNPs in PADI4 was significantly associated with susceptibility to not only anti-CCP-positive (adjusted OR 1.73, 95% CI 1.34 to 2.23) but also -negative RA (adjusted OR 1.75, 95% CI 1.15 to 2.68). A strong association with both non-erosive (adjusted OR 1.62, 95% CI 1.29 to 2.05) and erosive RA (adjusted OR 1.62, 95% CI 1.14 to 2.31) was observed for PADI4 haplotype. Gene-gene interactions between the homozygous RA-risk PADI4 haplotype and SE alleles were significant in both anti-CCP-positive (AP 0.45, 95% CI 0.20 to 0.71) and -negative RA (AP 0.61, 95% CI 0.29 to 0.92). Theses interactions were also observed for both non-erosive (AP 0.48, 95% CI 0.25 to 0.72) and erosive RA (AP 0.46, 95% CI 0.14 to 0.78). In contrast, no interaction was observed between smoking and PADI4 polymorphisms.Conclusions: A haplotype of nonsynonymous SNPs in PADI4 contributes to development of RA regardless of anti-CCP or erosive joint status. The homozygous PADI4 haplotype contri bution is affected by gene-gene interactions with HLADRB1 SE alleles.We are grateful to many research workers for assistance with sample preparation, data collection, and technical study. Dr. Bang's work was supported by a grant from the Korea Healthcare Technology R&D Project (A090706). Dr. Bae's work was supported by a grant from the Korea Healthcare Technology R&D Project (A084794 and A010252). Dr. Kang's work was supported by a grant from the Research Program for New Drug Target Discovery (M10748000231-08N4800-23110)
    corecore